Weiss Asset Management LP Purchases Shares of 2,634 United Therapeutics Co. (NASDAQ:UTHR)

Weiss Asset Management LP acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,634 shares of the biotechnology company’s stock, valued at approximately $579,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of United Therapeutics in the fourth quarter worth about $100,519,000. Comerica Bank increased its holdings in shares of United Therapeutics by 2,697.2% in the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after purchasing an additional 150,989 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of United Therapeutics by 309.7% in the 4th quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after acquiring an additional 101,419 shares during the last quarter. TD Asset Management Inc increased its position in United Therapeutics by 1,066.4% during the fourth quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock worth $18,240,000 after purchasing an additional 75,839 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in shares of United Therapeutics by 27.6% during the 4th quarter. Pacer Advisors Inc. now owns 312,799 shares of the biotechnology company’s stock worth $68,781,000 after buying an additional 67,738 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.6 %

UTHR stock traded down $1.61 during mid-day trading on Wednesday, reaching $267.54. The company had a trading volume of 266,997 shares, compared to its average volume of 456,887. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The company has a market capitalization of $11.87 billion, a price-to-earnings ratio of 12.73, a price-to-earnings-growth ratio of 4.13 and a beta of 0.54. The firm has a fifty day simple moving average of $248.67 and a 200 day simple moving average of $234.76. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $279.98.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.86 earnings per share. Analysts forecast that United Therapeutics Co. will post 24.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $275.78, for a total transaction of $992,808.00. Following the transaction, the director now owns 130 shares of the company’s stock, valued at $35,851.40. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, Director Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $275.78, for a total value of $992,808.00. Following the transaction, the director now owns 130 shares of the company’s stock, valued at $35,851.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $232.37, for a total value of $1,394,220.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $8,530,302.70. The disclosure for this sale can be found here. Insiders have sold a total of 157,128 shares of company stock valued at $38,053,129 over the last quarter. Company insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. Wells Fargo & Company increased their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. Oppenheimer lifted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $309.44.

View Our Latest Stock Analysis on United Therapeutics

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.